WO2002029023A8 - Nicastrin protein - Google Patents

Nicastrin protein

Info

Publication number
WO2002029023A8
WO2002029023A8 PCT/GB2001/004390 GB0104390W WO0229023A8 WO 2002029023 A8 WO2002029023 A8 WO 2002029023A8 GB 0104390 W GB0104390 W GB 0104390W WO 0229023 A8 WO0229023 A8 WO 0229023A8
Authority
WO
WIPO (PCT)
Prior art keywords
protein
nicastrin
nicastrin protein
idenfified
seqences
Prior art date
Application number
PCT/GB2001/004390
Other languages
French (fr)
Other versions
WO2002029023A1 (en
Inventor
Richard Joseph Fagan
John Paul Overington
Mark Basil Swindells
Malcolm Weir
Original Assignee
Inpharmatica Ltd
Richard Joseph Fagan
John Paul Overington
Mark Basil Swindells
Malcolm Weir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inpharmatica Ltd, Richard Joseph Fagan, John Paul Overington, Mark Basil Swindells, Malcolm Weir filed Critical Inpharmatica Ltd
Priority to AU2001292059A priority Critical patent/AU2001292059A1/en
Publication of WO2002029023A1 publication Critical patent/WO2002029023A1/en
Publication of WO2002029023A8 publication Critical patent/WO2002029023A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The invention relates to a protein termed Nicastrin, herein idenfified as an aminopeptidase and to the use of this protein and nucleic acis seqences from the encoding gene in the diagnosis, prevention and treatment of disease.
PCT/GB2001/004390 2000-10-02 2001-10-02 Nicastrin protein WO2002029023A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292059A AU2001292059A1 (en) 2000-10-02 2001-10-02 Nicastrin protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024086.1A GB0024086D0 (en) 2000-10-02 2000-10-02 Proteinase
GB0024086.1 2000-10-02

Publications (2)

Publication Number Publication Date
WO2002029023A1 WO2002029023A1 (en) 2002-04-11
WO2002029023A8 true WO2002029023A8 (en) 2002-07-04

Family

ID=9900507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004390 WO2002029023A1 (en) 2000-10-02 2001-10-02 Nicastrin protein

Country Status (3)

Country Link
AU (1) AU2001292059A1 (en)
GB (1) GB0024086D0 (en)
WO (1) WO2002029023A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220524A1 (en) 2006-04-25 2009-09-03 The University Of Tokyo Therapeutic agents for alzheimer's disease and cancer
CN105985405B (en) * 2015-02-13 2020-08-04 上海来益生物药物研究开发中心有限责任公司 3-amino-2-hydroxy-4-phenyl-valyl-isoleucine derivative and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
US6180384B1 (en) * 1998-02-02 2001-01-30 Smithkline Beecham Plc Compounds
WO2000060069A1 (en) * 1999-04-01 2000-10-12 The Governing Council Of The University Of Toronto A presenilin associated membrane protein and uses thereof
EP1242443A4 (en) * 1999-12-23 2005-06-22 Nuvelo Inc Novel nucleic acids and polypeptides
GB0005894D0 (en) * 2000-03-10 2000-05-03 Glaxo Group Ltd Assay

Also Published As

Publication number Publication date
AU2001292059A1 (en) 2002-04-15
GB0024086D0 (en) 2000-11-15
WO2002029023A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
WO2002000860A3 (en) Novel proteases
WO2002036771A3 (en) Imaging, diagnosis and treatment of disease
WO2003055913A3 (en) Secreted protein
WO2006016172A3 (en) Cell surface glycoprotein
WO2002029023A8 (en) Nicastrin protein
IL169256A0 (en) Metalloprotease proteins
WO2002033058A3 (en) Novel cysteine proteases and uses thereof
WO2007049065A3 (en) Vwfa, collagen and kunitz domain containing protein
WO2004053117A3 (en) Serine protease
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
EP1329504A4 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2002008393A3 (en) Serine protease from yersinia enterocolitica
WO2002088341A3 (en) P450 proteins
WO2002062976A3 (en) Serine proteases
WO2004041861A3 (en) Alpha macroglobulin family member
WO2002046380A3 (en) Protein kinase
WO2003054178A3 (en) Metalloprotease proteins
WO2002034901A3 (en) Protein kinase
WO2002044382A8 (en) Cytokine-like proteins
WO2004009633A8 (en) Serotonin receptor
WO2002062845A3 (en) Adhesion molecules
WO2004016654A8 (en) Il-8 like protein
WO2004024762A3 (en) Il-8 like protein
WO2003066844A3 (en) Cytochrome p450 protein
WO2002070558A3 (en) Nuclear hormone receptor ligand binding domain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP